As of August 21, 2026 3:55pm CDT, ABBV (ABBVIE INC., XNYS) traded at $266.40, +5.21 (+1.99%) on the day (delayed quote). StockMarketLoop's Market Position model puts the current profit ratio at 94.74%, with support near $250.41 and resistance near $265.03. Market capitalization: $462.7B.

Source: StockMarketLoop real-time market data (massive-aggregates-fallback-5m). Not investment advice.

ABBV

ABBVIE INC.

XNYS · CS

$266.40 +1.99% Delayed market data
Volume3,924,831
Market cap$462.7B
Market position94.74%
Support / resistance$250.41 / $265.03

About ABBVIE INC.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.

Explore ABBV

Open the interactive ticker terminal for charts, technical tools, market discussion and live modules.

Open ABBV ticker terminal
Observed August 21, 2026 3:55 pm CDT. Market data and model estimates only—not investment advice.
Stock Market LoopConnect. Learn. Share. Grow.
Stock Market Loop
Join StockmarketloopSign in to post, vote sentiment, save watchlists and view member tools.